Shares of The Medicines Company (NASDAQ:MDCO) have received an average rating of “Buy” from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $56.86.
Several research analysts have recently issued reports on the stock. J P Morgan Chase & Co restated a “buy” rating on shares of The Medicines Company in a report on Saturday, March 18th. Jefferies Group LLC restated a “buy” rating and issued a $62.00 target price on shares of The Medicines Company in a report on Wednesday, April 12th. ValuEngine cut shares of The Medicines Company from a “sell” rating to a “strong sell” rating in a report on Saturday, May 20th. Cowen and Company raised their target price on shares of The Medicines Company from $39.00 to $61.00 and gave the stock an “outperform” rating in a report on Wednesday, April 19th. Finally, Oppenheimer Holdings, Inc. began coverage on shares of The Medicines Company in a report on Monday, May 22nd. They issued a “market perform” rating and a $50.00 price target on the stock.
A number of institutional investors have recently made changes to their positions in the stock. Aviva Holdings Ltd. purchased a new position in shares of The Medicines Company during the first quarter valued at approximately $187,477,000. Iridian Asset Management LLC CT raised its position in shares of The Medicines Company by 218.7% in the first quarter. Iridian Asset Management LLC CT now owns 3,022,681 shares of the company’s stock valued at $147,809,000 after buying an additional 2,074,261 shares in the last quarter. Sarissa Capital Management LP purchased a new position in shares of The Medicines Company during the fourth quarter valued at approximately $59,462,000. Blue Ridge Capital L.L.C. purchased a new position in shares of The Medicines Company during the first quarter valued at approximately $53,790,000. Finally, Norges Bank purchased a new position in shares of The Medicines Company during the fourth quarter valued at approximately $22,599,000.
Shares of The Medicines Company (MDCO) traded down 1.38% on Monday, hitting $37.09. 1,335,993 shares of the stock were exchanged. The company’s market cap is $2.64 billion. The company has a 50 day moving average of $42.64 and a 200 day moving average of $43.88. The Medicines Company has a 52-week low of $30.80 and a 52-week high of $55.95.
The Medicines Company (NASDAQ:MDCO) last issued its earnings results on Wednesday, April 26th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by $0.31. The Medicines Company had a negative return on equity of 19.09% and a negative net margin of 91.25%. The firm had revenue of $24.20 million during the quarter, compared to the consensus estimate of $37.76 million. During the same quarter in the prior year, the business posted ($1.03) EPS. The firm’s revenue for the quarter was down 51.9% on a year-over-year basis. Equities research analysts forecast that The Medicines Company will post ($5.97) earnings per share for the current year.
About The Medicines Company
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.